FDA approves Lisraya, first targeted therapy for dermatomyositis
New CapabilitiesOnce-daily pill for rare autoimmune disease cuts steroid dependence
Today: Roivant investor call scheduledNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 2 hours agoThe FDA approved Lisraya on August 27, 2026, clearing the first targeted therapy ever approved for dermatomyositis, a rare autoimmune disease that inflames skin and weakens muscles. The once-daily pill showed gains in skin disease, muscle strength, and physical function within four weeks.
Until now, doctors managed dermatomyositis with broad immunosuppressants and steroids that carry long-term side effects. Lisraya's steroid-sparing results could change how the roughly 5,000 Americans with the condition are treated.
Why it matters
Dermatomyositis patients finally have a pill that targets their disease's cause instead of suppressing the whole immune system, and it cuts steroid dependence.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
Biopharmaceutical company that developed Lisraya (brepocitinib) for dermatomyositis.
Holding company that builds and operates focused biotech subsidiaries, including Priovant.
US agency that regulates drug approvals and drug safety.
Advocacy group representing people with muscle diseases including dermatomyositis.
Timeline
January 2021 August 2026
-
Roivant investor call scheduled
Today Corporate UpdateRoivant will host an investor call at 8:00 a.m. ET to discuss the approval and launch.
-
FDA approves Lisraya for dermatomyositis
Regulatory ApprovalFDA approved Lisraya (brepocitinib) 30 mg as the first targeted therapy for adults with dermatomyositis, following Priority Review and Orphan Drug Designation.
-
Lisraya launches in the US
LaunchThe drug is available immediately through specialty pharmacies; eligible patients may pay as little as $0 per month through the My Compass Support program.
-
Pfizer licenses brepocitinib to Priovant
LicensingPfizer licensed brepocitinib to Priovant Therapeutics, a joint company it created with Roivant Sciences.
Historical Context
2 moments from history that rhyme with this story — and how they unfolded.
Soliris (eculizumab) approval (2007)
The FDA approved Soliris, the first complement inhibitor, for paroxysmal nocturnal hemoglobinuria, a rare blood disease previously managed with transfusions and supportive care.
Soliris became the standard of care for the disease and proved targeted therapies could command premium pricing in rare diseases.
It set a commercial template for ultra-rare disease drugs with small patient populations and high per-patient costs.
Like Soliris, Lisraya is a first-targeted-therapy for a rare disease with a small US population, testing how far mechanism-based drugs can reshape rare disease care.
Xeljanz (tofacitinib) approval (2012)
The FDA approved Xeljanz, the first JAK inhibitor, for rheumatoid arthritis. It offered a daily pill targeting immune pathways instead of injected biologics or broad immunosuppression.
Xeljanz transformed RA care and became a blockbuster, validating JAK inhibition as a treatment strategy.
Post-marketing safety trials later linked higher doses to cardiovascular events and malignancy, prompting FDA boxed warnings and restricted use.
Lisraya is a TYK2/JAK1 inhibitor, so it faces the same long-term safety scrutiny that reshaped Xeljanz's label.
